Synergistic Therapeutic System for Corneal Endothelial Diseases

A novel system integrating (T)EW-7197 with distinct technologies such as AI, IoT, blockchain, and nanomaterials to provide more effective and personalized treatment options for corneal endothelial diseases.

The original patent disclosed the use of (T)EW-7197 for treating or preventing corneal endothelial diseases. However, the patent did not address the limitations of current treatment methods, such as the lack of personalized dosing regimens, inefficient data management, and limited therapeutic delivery options. The new inventive concept addresses these limitations by combining (T)EW-7197 with innovative technologies to create a more powerful system.

The synergistic therapeutic system comprises a combination of (T)EW-7197 and at least one of the following: a blockchain-based data management module, an AI-driven dosing regimen, a biodegradable polymer matrix, a portable IoT-enabled device, or a novel nanomaterial-based delivery system. The system enables personalized treatment of corneal endothelial diseases, real-time monitoring of corneal endothelial cell density, and targeted release of the therapeutic compound to the corneal endothelium.

The new claims introduce a synergistic combination of (T)EW-7197 with distinct technologies, which is not obvious from the original patent. The integration of these technologies provides a novel and non-obvious solution for treating or preventing corneal endothelial diseases.

Alternative embodiments of the inventive concept could include the use of different AI algorithms, various blockchain architectures, or diverse nanomaterials for therapeutic delivery. Additionally, the system could be adapted for treating other ocular diseases or conditions.

The synergistic therapeutic system has significant commercial potential in the ophthalmology market, particularly for the treatment of corneal endothelial diseases such as Fuchs' endothelial corneal dystrophy. The system's ability to provide personalized treatment options, real-time monitoring, and targeted therapeutic delivery could revolutionize the field of ophthalmology and improve patient outcomes.